The malaria parasite has co-evolved with its human host as each organism struggles for resources and survival. The scars of this war are carried in the human genome in the form of polymorphisms that confer innate resistance to malaria. Clinical, epidemiological and genome-wide association studies have identified multiple polymorphisms in red blood cell (RBC) proteins that attenuate malaria pathogenesis. These include well-known polymorphisms in haemoglobin, intracellular enzymes, RBC channels, RBC surface markers, and proteins impacting the RBC cytoskeleton and RBC morphology. A better understanding of how changes in RBC physiology impact malaria pathogenesis may uncover new strategies to combat the disease.
Introduction
Plasmodium falciparum malaria remains one of the most problematic infectious diseases globally, causing an estimated 438 000 deaths annually (World Health Organization (WHO), 2016). However, this number represents only a small proportion of the total number of individuals who are infected each year with the malaria parasite. The majority of people who are infected with malaria never exhibit clinical symptoms. There is a natural and complex variation in the pathogenesis and clinical presentation of malaria, which is influenced by host age, immunity and genetic background, as well as by environmental conditions and parasite genetics (Manjurano et al, 2015) . Host genetic factors are estimated to account for one quarter of the total variability in malaria severity (Mackinnon et al, 2005) and malaria infection is thought to be the evolutionary driving force behind multiple human genetic human polymorphisms and disorders. Many of these host genetic polymorphisms are expressed in red blood cells (RBCs) . Understanding the molecular basis of these polymorphisms may shed additional light on the variation in human susceptibility to malaria and offer insight into mechanisms of malaria pathogenesis.
In this review we primarily focus on P. falciparum, the most deadly species, though other Plasmodium species can also cause malaria in humans (specifically, P. vivax, P. malariae, P. ovale and P. knowlesi). The term 'malaria' refers to a range of clinical presentations seen in children and adults infected with the Plasmodium parasite. 'Parasitaemia' is a non-specific term that is typically used to describe the simple presence of malaria parasites or to reference the level of parasite-infected RBCs, but does not include any clinical information. Hence, individuals with malaria parasites and any level of clinical severity can be referred to as 'parasitaemic'. In many malaria-endemic areas, significant numbers of individuals have what is referred to as 'asymptomatic malaria' or 'asymptomatic parasitaemia' or 'subclinical malaria'. These individuals have low-level parasitaemia, but remain clinically asymptomatic. This is usually thought to occur in individuals with sufficient levels of immunity to keep parasite replication in check (Bousema et al, 2014) . However, the mechanisms responsible for this non-sterile immunity are unclear, as is the question of whether or not these individuals should be treated with anti-malarial medications (Chen et al, 2016) . It is also impossible to determine if an individual with 'asymptomatic malaria' is clinically stable or will soon develop clinical malaria.
Malaria is considered 'uncomplicated' when non-specific symptoms are present without clinical or laboratory signs of organ dysfunction. Symptoms can include: fever, sweating, general weakness, enlarged spleen, mild jaundice, liver enlargement and mildly increased respiratory rate. Malaria is considered 'severe' when it is complicated by serious organ failure(s) or significantly abnormal haematological or metabolic indices, highlighting clinical disease and leading to increased morbidity and mortality. These manifestations can include cerebral malaria, severe anaemia due to haemolysis, haemoglobinuria, acute respiratory distress syndrome, abnormalities in blood coagulation, acute kidney failure, metabolic acidosis, hypoglycaemia and hyperparasitaemia (where more than 5% of RBCs are infected). Severe malaria is not a single entity. The WHO defines severe malaria as including one of the following: impaired consciousness, acidosis, hypoglycaemia, severe anaemia, renal impairment/acute kidney injury, jaundice, pulmonary oedema, significant bleeding, shock and hyperparasitaemia (WHO, 2014) .
Host protection from, or immunity against, severe malaria does not always translate into protection from uncomplicated or asymptomatic malaria. Each of the RBC variants discussed in this review have distinct effects on malaria pathogenesis and therefore have unique effects on the clinical presentation of malaria (Fig 1) . Increased parasite burden may cause increased disease through mechanisms such as elevated haemolysis and enhanced parasite biomass cytoadhesion in the peripheral vasculature, however, the relationship between parasite mass and disease symptoms is not always linear (Gonc ßalves et al, 2014) . Individuals can develop severe malaria without a high parasite burden if they have a strong immune response with high levels of proinflammatory cytokines. While previous exposure to malaria typically leads to immune memory and reduces parasite replication and pathogenesis, the relationship between malaria immune response and disease symptoms is still very complex and can vary with age, lifetime exposure frequency, local transmission intensity and seasonality, and host and parasite genetics. Furthermore, in many places the relationship between age and frequency of severe malaria or overall malaria burden is shifting upwards as transmission dynamics change and exposure is reduced. We do not further discuss these complex points in detail but the reader is referred to relevant discussions by Griffin et al (2014) and Cameron et al (2015) . Diagram of RBC and RBC proteins with known links to malaria pathogenesis. G6PD, glucose-6-phosphate dehydrogenase; GYPA, glycophorin A; GYPB, glycophorin B; GYPC, glycophorin C; PK, pyruvate kinase; RBC, red blood cell.
Haemoglobinopathies

Sickle cell trait
Human haemoglobin is comprised of two a-globin and two b-globin proteins; the sickle cell mutation occurs in the gene encoding b-globin (HBB), causing a glutamic acid to valine switch at the 6th codon. This simple amino acid change leads to RBC sickling in homozygous individuals (HbSS genotype). The HbSS and HbAS (heterozygous) genotypes are commonly found in populations from Sub-Saharan Africa (HbS allele frequency ranging up to 18%; Piel et al, 2013a) . In 2010 alone, nearly 6 million neonates were estimated to carry the sickle cell trait allele (approximately 300 000 of which are HbSS) (Piel et al, 2013a) . The link between sickle cell trait and malaria protection was first hypothesized in the 1950s.
Since then, it has been unequivocally shown that the heterozygous HbAS genotype protects against severe malaria [discussed and analysed in Allison (2009) ; Taylor et al (2012 Taylor et al ( , 2013 ]. Specifically, studies in West Africa have found sickle cell trait affords approximately 90% reduction against severe malaria and that the HbAS genotype protects against uncomplicated malaria by approximately 30% (Taylor et al, 2012) . This has been further confirmed by several genome wide association studies (Malaria Genomic Epidemiology Network, 2014) and other methods, such as family-based association and case-control analysis (Ackerman et al, 2005) . Less clear is the impact of the HbAS genotype on the risk of asymptomatic parasitaemia.
There are multiple cellular and molecular mechanisms that may impact the pathogenesis of falciparum malaria in people with the HbAS genotype, and the picture is incomplete despite decades of research. First, the work of many authors has shown that invasion and growth of P. falciparum in vitro within HbAS RBCs is reduced in low oxygen tension growth conditions (Friedman, 1978; Goheen et al, 2016) Some have proposed that the increased sickling of infected HbAS RBCs may be a mechanism for impaired growth (Luzzatto et al, 1970) . However, more recent research by LaMonte et al (2012) adds another dimension, showing differential effects of host microRNAs (miRNAs) from HbAS and HbSS RBCs on intracellular growth of malaria parasites. HbAS and HbSS RBCs have higher levels of specific host miRNAs, which can inhibit translation of parasite enzymes that are important for growth and development. Additionally, treatment with antisense oligonucleotides directed against these miRNAs partially rescue parasite growth in HbAS RBCs in vitro (LaMonte et al, 2012) .
Second, the HbAS genotype decreases the adhesive properties of parasitized RBCs mediated through P. falciparum erythrocyte membrane protein 1 (PfEMP1). Altered cytoskeletal properties of HbS-containing RBCs have been hypothesized to impact parasite protein trafficking to the RBC surface (Cyrklaff et al, 2011; Kilian et al, 2015) , and thereby reduce cytoadhesion (Cholera et al, 2008) . Third, the HbAS genotype has an effect on the immune system. It is postulated that reduced parasite invasion and growth in HbAS RBCs indirectly gives the immune system time to increase its activity and more effectively combat infection. There is also evidence to suggest that the HbAS genotype favourably alters the immune response directly by increasing phagocytosis of infected RBCs, or possibly through influencing the induction of inflammatory cytokines following endothelial activation (due to altered cytoadhesion properties) [discussed in Mangano et al (2015) ; Cholera et al (2008) ; Taylor et al (2013) ].
The protective effect of the HbAS genotype comes at a cost. Homozygous HbSS individuals suffer from the physiological effects of sickling RBC deformations: microvascular obstruction and haemolysis leading to multiple downstream health deficits, frequent pain crises and reduced lifespan. Lifespan has historically been estimated in the 5th decade (Platt et al, 1994) , though that continues to increase with modern medicine in the developed world; in the developing world, lifespan for those with sickle cell anaemia is even more limited. Pathologies such as microvascular obstruction and haemolysis probably contribute to the observation that, though afforded more protection against infection, when HbSS individuals do get malaria they face increased morbidity and mortality McAuley et al, 2010) . Individuals with the HbAS genotype have a normal lifespan and are usually haematologically asymptomatic. But during extreme circumstances, such as dehydration and high-intensity physical activity, complications including exertional rhabdomyolysis, splenic infarction and papillary necrosis, can occur (Tsaras et al, 2009; Nelson et al, 2016) . The widespread prevalence of HbAS despite the cost of HbSS inheritance demonstrates the profound advantage given by HbAS in the battle against malaria.
Haemoglobin C
The Haemoglobin C (HbC) mutation (HbAC for heterozygotes; HbCC for homozygotes) also involves a point mutation at the 6th codon in the HBB gene, however it causes a glutamic acid to lysine substitution. The HbC polymorphism is most common in West Africa, with prevalence reported as high as 15% in parts of Burkina Faso (Piel et al, 2013b) . For severe falciparum malaria, evidence of protection by the HbC variant is clear. Individuals with the homozygous HbCC genotype show 80% reduction in the risk of severe malaria and heterozyogous HbAC individuals show 30% reduction (Taylor et al, 2012) . Further strong evidence for overall protection comes from a recent genome-wide association study (GWAS), which concluded that for each copy of the HbC allele, risk for severe malaria was reduced by 29% (Malaria Genomic Epidemiology Network, 2014) . For uncomplicated malaria, the picture is confusing: some studies show protection for HbAC and HbCC, but others do not. A meta-analysis of available studies concluded that the protection from malaria by HbC genotype mutations is unknown (Taylor et al, 2012) . Similarly, there is no conclusive evidence that HbAC or HbCC provides protection against asymptomatic malaria.
The molecular mechanisms of protection from malaria by the HbC genotypes are not fully elucidated, but, again, the three areas of parasite growth and development, adhesion of parasitized RBCs to endothelial cells and immune system changes, have all been implicated. In vitro studies indicate reduced growth in HbCC RBCs, and there is additional evidence of normal invasion but reduced schizont lysis and merozoite egress Fairhurst et al, 2003) . Growth in HbAC RBCs has been reported as normal Olson & Nagel, 1986) . Similar to results with the HbAS mutation, both the HbAC and HbCC genotypes can result in altered PfEMP1 expression on the infected RBC surface (Fairhurst et al, 2005; Cholera et al, 2008) . Further microscopic analysis has revealed an altered cytoskeleton in RBCs from donors with the HbAC genotype, which was hypothesized to impair trafficking of parasite proteins to the RBC surface (Cyrklaff et al, 2011; Kilian et al, 2015) . The impact of the HbC variants on the immune system are even less clear. Thus, although there are hints of reduced intracellular parasite growth and impaired cytoadhesion, the mechanisms by which the HbCC and HbAC genotypes provide protection against malaria remain an open question.
Clinically, the trade-off of inheriting the most protective form, HbCC, is mild haemolysis and anaemia, while those with the HbAC genotype are asymptomatic. More significant clinical issues are found when HbC is co-inherited with HbS or b-thalassaemia (Williams & Weatherall, 2012) , which could explain the more limited global prevalence of HbC compared to other haemoglobinopathies.
Haemoglobin E
The Haemoglobin E (HbE) mutation is a point mutation that results in a glutamic acid to lysine switch at position 26 of the HBB gene. It is most commonly found in parts of Southeast Asia and India, and reaches a prevalence up to 60% in some areas (Williams & Weatherall, 2012) . HbE protection against malaria in homozygotes (HbEE) and in heterozygotes (HbAE) is not well characterized, and the available data are contradictory and inconclusive.
Little work has been done to characterize the mechanisms by which HbE might contribute to reduced parasitaemia or malaria protection. Again, three broad categories of effects are relevant: reduced parasite growth and development, altered adhesion of parasitized RBCs to endothelium, and impact on the immune system. In vitro studies of HbEE and HbAE RBCs have found reduced invasion and growth in HbEE (Bunyaratvej et al, 1992; Chotivanich et al, 2002) and HbAE (Chotivanich et al, 2002) RBCs. Clearly, more work needs to be done to answer further questions about the protective impact of HbE. The trade-off for harbouring the HbE trait is minimal and limited to mild anaemia (Taylor et al, 2013) .
Thalassaemias
The two a-globin and b-globin chains that combine to form human haemoglobin are encoded by two a-globin genes (HBA1 and HBA2) and one b-globin gene (HBB). The term 'thalassaemias' collectively refers to a number of different genetic mutations that result in reduced or absent expression of one or more of these globin alleles. Specifically, individuals described as having 'a-thalassaemia' can have the loss of one or more a-globin allele(s); there is also HbH disease (loss of 3 a-globin alleles) and, finally, hydrops fetalis (loss of all 4 a-globin alleles and incompatible with life). Individuals with mutations in HBB can also have a range of genetic defects, referred to as 'b-thalassaemia', including b-thalassaemia minor (reduced expression of one b-globin allele), and b-thalassaemia major (reduced expression of both b-globin alleles) [reviewed in Taylor et al (2013) ]. Geographically, the thalassaemias can be found worldwide, with mild a-thalassaemias reaching prevalence of 10-20% throughout a geographical belt spanning Sub-Saharan Africa, the Middle East, India, and Southeast Asia (and can even be found at much higher frequencies in selected parts of Southeast Asia). b-thalassaemia is prevalent in the Mediterranean and a few parts of Sub-Saharan Africa, ranging from 1% to 20% prevalence with highest prevalence in the Mediterranean (Galanello & Origa, 2010; Williams & Weatherall, 2012; De Sanctis et al, 2017) . HbH rates are highest in Southeast Asia where a-thalassaemia alleles are most prevalent. It is estimated that 60 000 people with symptomatic b-thalassaemia disorders are born annually, with approximately 200 000 people registered as receiving treatment for b-thalassaemia major globally (Galanello & Origa, 2010) . In total, it is estimated that just over 1Á5% of the world's population harbours an a-or bthalassaemia allele (Rund & Rachmilewitz, 2005) .
There is clear protection from malaria by each of the thalassaemias. In fact, the original 'malaria hypothesis' connecting geographic prevalence of genetic haemoglobin alterations to malaria prevalence was formulated by Haldane in the 1950s as a result of his observations on the presence of thalassaemia-causing alleles in people of Mediterranean descent where malaria was formerly endemic (Haldane, 1949) . Metaanalysis of studies which examined the prevalence of a-thalassaemia in children with severe malaria and healthy children found an odds ratio for severe malaria of 0Á63 for homozygote a-thalassaemia and 0Á83 for heterozygotes (Allen et al, 1997; Mockenhaupt et al, 2004; Williams et al, 2005; May et al, 2007; Taylor et al, 2012) . Interestingly, such protection from severe malaria is eliminated by co-inheritance of the HbAS allele, perhaps providing an explanation for why a-thalassaemia mutations are not as prevalent in many parts of Africa Lopera-Mesa et al, 2015) . Protection from uncomplicated malaria is less clear.
Some studies found decreased incidence of malaria with any form of a-thalassaemia Enevold et al, 2008) , while others actually found no difference (Wambua et al, 2006) or increased incidence (Williams et al, 1996) compared to normal genotype. Meta-analysis concluded that a-thalassaemia carriers were not protected against uncomplicated malaria (Taylor et al, 2012) . Finally, there is no clear data to support a protective effect of a-thalassaemia against asymptomatic parasitaemia, both in terms of the presence and density of parasites (Wambua et al, 2006; Fowkes et al, 2008; Shekalaghe et al, 2009 ).
There are far fewer comprehensive studies on b-thalassaemia and malaria protection. The earliest work was done in Sardinia in the 1960s, correlating higher prevalence of b-thalassaemia in areas of increased historical malaria transmission, particularly looking at this genetic allele prevalence in relation to village altitude variance (Siniscalco et al, 1961 (Siniscalco et al, , 1966 . Beyond this, the majority of available evidence comes from two studies that were both done in Northern Liberia. One found uncomplicated malaria cases were less likely to involve people with b-thalassaemia (Willcox et al, 1983a) and the other found no differences, although they did report lower parasite densities in those with b-thalassaemia (Willcox et al, 1983b) .
As with the haemoglobinopathies, the precise molecular mechanisms by which the thalassaemias protect against malaria disease are unclear. Minimal changes have been observed in parasite invasion and growth in RBCs from individuals heterozygous for the a-thalassaemia genotype. For RBCs from individuals with homozygote a-thalassaemia, studies show conflicting and thus inconclusive evidence regarding growth and invasion differences (Friedman, 1979; Ifediba et al, 1985; Luzzi et al, 1991a; Bunyaratvej et al, 1992; Williams et al, 2002) . RBCs from those with HbH disease show reduced growth and invasion (Ifediba et al, 1985; Brockelman et al, 1987; Chotivanich et al, 2002) . Some studies show no differences in invasion or growth in RBCs from individuals with b-thalassaemia (Luzzi et al, 1991a; Bunyaratvej et al, 1992) , but one study did find reduced growth (Brockelman et al, 1987) . It has also been reported that RBCs missing either one copy of HBA1/2 or HBB support less malaria parasite growth when cultivated at high oxygen tension (Friedman, 1979) . Interestingly, invasion is frequently reduced in RBCs harbouring both a b-globin thalassaemia mutation and HbE (Brockelman et al, 1987; Bunyaratvej et al, 1992; Chotivanich et al, 2002) .
Multiple investigators have observed reduced rosetting and reduced binding to endothelial cells in parasitized RBCs from individuals with a-thalassaemia and b-thalassaemia (Udomsangpetch et al, 1993; Carlson et al, 1994; Butthep et al, 2006; Krause et al, 2012 ). Yet, there are other conflicting reports on cytoadhesion and PfEMP1 expression in RBCs from individuals with a-thalassaemia (Luzzi et al, 1991b; Williams et al, 2002; Opi et al, 2014) . Interestingly, as mentioned above, there is a reduction in protection against malaria in individuals who carry both HbAS and a-thalassaemia May et al, 2007; Crompton et al, 2008) . Investigating this phenomenon further with in vitro studies, Opi et al (2014) found that co-inheritance abrogated the reduced PfEMP1 expression, cytoadhesion and rosetting typically observed with HbAS. The mechanism for this remains unknown (Opi et al, 2014) . Studies have found that anti-malarial antibodies bind parasitized RBCs from individuals with thalassaemia more than RBCs from normal individuals (Luzzi et al, 1991a,b) and undergo increased phagocytosis (Ayi et al, 2004 ) -both of which may result in enhanced immune clearance of parasitized RBCs from individuals with thalassaemias [discussed in Taylor et al (2013) ]. Finally, another interesting possible phenomenon to discuss regarding mechanisms of protection against severe malaria involves the finding by Williams et al (1996) of increased uncomplicated malaria infections in those with a-thalassaemia in Vanuatu. This increased incidence was primarily due to P. vivax infections in young children, and the authors speculated cross-species protective immune development might benefit these carriers against more lethal falciparum infections (Williams et al, 1996) .
The drawbacks of maintaining the thalassaemic genetic mutations within a population can be significant. For example, hydrops fetalis (missing all a-globin alleles) is incompatible with life. HbH disease (missing 3 copies of a-globin) as well as b-thalassaemia major result in a severely reduced lifespan along with chronic and severe anaemia. Disease severity varies with HbH disease, but typically those with b-thalassaemia major do not survive past 30 years of age (Muncie & Campbell, 2009 ). b-thalassaemia minor and the a-thalassaemia traits are much less consequential, and are often asymptomatic and associated with only mild anaemia (Taylor et al, 2013) .
Enzymatic deficiencies
Glucose-6-phosphate dehydrogenase deficiency Glucose-6-phosphate dehydrogenase (G6PD) catalyses the first step in the pentose phosphate shunt, which ultimately produces NADPH, a reducing agent. NADPH is a critical cofactor for glutathione reductase, which generates the reduced form of glutathione and is critical for lowering oxidative stress in RBCs. The human gene for G6PD (G6PD) contains 13 exons and encodes 515 amino acids. G6PD is a monomer, but the active enzyme is a dimer, which requires both NADP and FAD (riboflavin) for its activity. Over 140 mutations have been identified, each of which results in various degrees of change in the enzymatic activity. Over 400 variants have been characterized that have normal levels of G6PD activity. To compound confusion, all of the 400 variants with normal G6PD levels are considered wild type and are referred to as G6PD B. One common variant, which is found in 20-30% of people of African descent, and is therefore often discussed in studies linking malaria protection to G6PD deficiency, is referred to as G6PD A+. G6PD A+ has a single amino acid substitution at position 376. Another common variant is G6PD AÀ. All G6PD AÀ variants have a mutation at nucleotide 376, which also is the nucleotide substitution characteristic of G6PD A+. However, the G6PD AÀ variants have a second mutation, which is usually at nucleotide 202 or 680 or 968 (Luzzatto et al, 2016) .
The WHO classifies the different G6PD variants into clinically important categories according to the magnitude of the enzyme deficiency and the severity of haemolysis associated with each variant (WHO Working Group, 1989) . Class I variants, which are rare, have severe enzyme deficiency (less than 10% of normal) and chronic haemolytic anaemia. Class II variants also have severe enzyme deficiency, but there is usually only intermittent haemolysis associated with infection, drugs or chemicals. Class III variants have moderate enzyme deficiency (10-60% of normal) with intermittent haemolysis usually associated with infection, drugs or chemicals. Note that most G6PD AÀ variants fall into Class III. Class IV variants have no enzyme deficiency or haemolysis. Class V variants have increased enzyme activity (WHO Working Group, 1989).
X-linked genetic mutations causing G6PD deficiencies are among the most common genetic mutations globally and affect an estimated 400 million people [reviewed in Cappellini and Fiorelli (2008) ]. Given the distribution of mutations throughout Africa, the Mediterranean, Middle East and Asia, and their independent development in multiple distinct populations, G6PD deficiency has been hypothesized to have arisen due to malaria pressure (Luzzatto et al, 2016 ). Yet, despite this long standing hypothesis and a large number of studies, there is no consensus on whether G6PD protects against falciparum malaria. Controversy surrounds the question of whether heterozygous and homozygous females are protected, and even the previously commonly held belief that hemizygote males are protected is no longer clear. Very recent comprehensive studies report nearly the exact opposite results: They suggest that heterozygote females are the only ones protected against severe malaria (Malaria Genomic Epidemiology Network, 2014; Sirugo et al, 2014; Uyoga et al, 2015) or that hemizygote males and homozygote females are the only ones protected against severe malaria (Guindo et al, 2007) .
A description of the dozens of studies that have been done to date to examine the question of whether G6PD deficiency protects against clinical malaria is beyond the scope of this review; instead, we will discuss some of the reasons why these studies have often conflicted. There are the typical issues: many of the studies have relatively small sample sizes, vary in the immune status of the subjects, and some are village surveillance surveys while others are hospital-based studies. This is all further complicated by the tremendous diversity in the G6PD gene mutations, which result in a large diversity of enzyme levels. Even amongst donors with the same genetic variant of G6PD, there is diversity in the levels of enzyme activity. In addition, since the gene is carried on the X chromosome, X inactivation of one allele in the RBCs results in heterogeneity within the RBC population of heterozygous females. Finally, there are a wide variety of inconsistencies in the methodologies used to characterize G6PD deficiency (for example, genetic sequencing versus analysis of enzymatic activity) in the epidemiological studies linking malaria and G6PD deficiency. All of these differences are compounded by the fact that many of the studies use different definitions of clinical malaria, which makes it difficult to draw conclusions and compare studies. To address this problem, a recent sub-study from a large multi-centre casecontrol study of severe malaria (Malaria Genomic Epidemiology Network, 2014) reported an analysis of multiple allelic forms of G6PD deficiency in 11 countries from Africa and Asia using a set of 135 single nucleotide polymorphisms (Clarke et al, 2017) . This study reported that increasing levels of G6PD deficiency are associated with decreasing risk of cerebral malaria, but with increased risk of severe malarial anaemia. These findings indicate that an evolutionary tradeoff between the different clinical outcomes of P. falciparum infection have also probably contributed to the conflicting reports of G6PD polymorphisms association with malaria protection, Unfortunately, the literature on the molecular mechanisms for G6PD protection is also plagued by the same issues as those discussed above for the clinical studies, and there are many conflicting results. As reviewed by Ruwende and Hill (1998) , there is evidence for two ways in which the increased oxidative stress in G6PD-deficient RBCs may protect against malaria: (i) it causes increased Heinz body formation and methaemoglobin formation, which results in either RBC lysis or enhanced phagocytosis of infected RBCs, and (ii) it decreases the rate of intra-erythrocytic parasite replication.
The clinical consequences of G6PD deficiency include increased risks of both neonatal jaundice and extensive haemolysis induced by excess oxidative stress. The most common triggers for haemolysis in this patient population are medications (including some anti-malarials), particular foods (most famously fava beans), and several types of infections [reviewed in Luzzatto et al (2016) ].
Pyruvate kinase deficiency
Pyruvate kinase (PK) deficiency deserves mention as the other enzymatic deficiency that has been found to associate with malaria protection, although it is less well studied. This enzyme is involved in the rate-limiting step of glycolysis and is thus important for energy production in RBCs, which lack mitochondria. Several mutations are known in humans (Zanella et al, 2005) . The clinical consequence of homozygosity is severe haemolytic anaemia, which has made homozygotes rare (Zanella et al, 2005; Ayi et al, 2008) . Ayi et al (2008) studied P. falciparum growth in PK-deficient RBCs and found reduced invasion and enhanced phagocytosis. Mouse studies have found that PK deficiency protects against malaria (Min-Oo et al, 2003 , 2004 , as have other in vitro studies using RBCs from PK-deficient donors (Durand & Coetzer, 2008) . Clinical research has also found reduced numbers of PK-deficient individuals with P. falciparum infection in Thailand (van Bruggen et al, 2015) . Together, this evidence suggests this is yet another human genetic variant that is a scar from the war with malaria.
RBC morphology and the cytoskeleton
There are several different kinds of genetic mutations that affect the RBC membrane and impact RBC shape. The most frequent mutations are seen in cytoskeletal components and associated membrane proteins, such as spectrin or band 3 or 4Á1 proteins. Multiple categories of morphological RBC disorders exist, including: (i) Hereditary elliptocytosis, a heterogeneous disorder caused by various mutations in spectrin. This disorder has a clinical manifestation that can range from no effect to severe haemolytic anaemia. (ii) Hereditary pyropoikilocytosis, a severe haemolytic anaemia type of hereditary elliptocytosis that results from complete spectrin deficiency. (iii) Hereditary spherocytosis, another heterogeneous cytoskeletal defect in either spectrin, ankyrin, band 3 or protein 4Á2; and (iv) Southeast Asian Ovalocytosis (SAO), a disorder characterized by oval-shaped RBCs and decreased deformability, which may be linked to a deletion in band 3 protein (Facer, 1995; Gallagher, 2004; Delaunay, 2007) .
Most of these disorders are inherited in an autosomal dominant fashion and are not classified based on genetics, but on phenotypes. Mutations causing these RBC disorders result in reduced integrity of the RBC cytoskeleton. Speculation that these conditions arose evolutionarily due to malaria pressure is based on observations of the high prevalence of these polymorphisms in people of African descent. For example, hereditary elliptocytosis is 30 times more prevalent in people of African descent than in Caucasians (Lecomte et al, 1988; Glele-Kakai et al, 1996; Dhermy et al, 2007) .
The mechanisms are not well understood, but there is clear evidence of malaria protection associated with these altered RBC morphologies both in vivo and in vitro. Clinically, most of the evidence comes from case studies with SAO, which show reduced severity and prevalence of malaria in SAO patients (Serjeantson et al, 1977; Cattani et al, 1987; Foo et al, 1992; Genton et al, 1995; Allen et al, 1999) . Protection against severe malaria was often profound (sometimes with an odds ratio of 0 reported due to absence of severe malaria cases amongst those with the band 3 deletion) (Foo et al, 1992; Genton et al, 1995; Allen et al, 1999) , and protection against malaria was not limited to falciparum malaria, but also extended to P. vivax and P. malariae (Serjeantson et al, 1977; Cattani et al, 1987; Foo et al, 1992) . SAO has also been found to reduce parasite growth in vitro (Castelino et al, 1981; Schulman et al, 1990; Bunyaratvej et al, 1997) . Despite little published evidence of clinical protection with the other types of morphological disorders, in vitro studies have suggested reduced parasite growth in RBCs from people with hereditary spherocytosis and elliptocytosis (Schulman et al, 1990) . Dhermy et al (2007) studied falciparum growth in RBCs harbouring different elliptocytic spectrin mutations and found overall significantly reduced growth, altered development and reduced merozoite invasion, and that the growth and invasion deficits were more apparent with each cumulative replication cycle. The parasite growth deficiencies in RBCs from individuals with hereditary elliptocytosis and SAO could both be caused by the mechanical inhibition of RBC invasion by merozoites (Facer, 1995) . Certainly there are many plausible links between cytoskeletal defects and reduced parasite growth or ability to cause disease, which will continue to be elucidated by further study. For people harbouring cytoskeletal mutations, these morphological RBC changes typically cause few clinical problems and most remain asymptomatic throughout their lifetime. However there are some cytoskeletal mutations where splenomegaly can occur when the less deformable mutant RBCs get 'caught' in the microvasculature of the spleen (Barcellini et al, 2011) .
Blood groups
ABO blood groups
All blood group types exist globally, so the connection to malaria protection is less intuitively obvious than the other RBC mutations presented above. Early studies showed conflicting results. However, recent comprehensive studies have definitively shown that individuals with blood type O are less susceptible to severe malaria and non-type O individuals are at increased risk in Sub-Saharan Africa and India (Rowe et al, 2007; Fry et al, 2008; Jallow et al, 2009; Tekeste & Petros, 2010; Deepa et al, 2011; Panda et al, 2011; Gupte et al, 2012; Afoakwah et al, 2016) . The correlations appear to be strongest between blood type and severe clinical disease, not with parasitaemia levels or uncomplicated malaria infection. The protection is significant, with the odds ratio for increased risk of severe malaria in non-O type blood groups ranging from 1Á26 to 2Á95 (Rowe et al, 2007) .
Studies on the molecular pathophysiology behind differential susceptibility to severe malaria in individuals with different ABO blood groups consistently points to rosetting, which occurs when infected RBCs adhere to and clump with uninfected RBCs. This potentially contributes to disease pathology by inducing inflammation and obstructing blood flow in small vessels (Kaul et al, 1991) . Rosetting severity correlates with disease severity and parasite burden, however other possible mechanisms that may contribute to disease include enhanced immune evasion in the setting of rosettes [reviewed in Rowe et al (2009)] . Many in vitro studies examining the rosetting potential of RBCs of different blood types found larger and more stable rosettes, as well as an increased (Carlson & Wahlgren, 1992; Udomsangpetch et al, 1993; Rowe et al, 1995; Chotivanich et al, 1998; Barragan et al, 2000) . It has also been shown that PfEMP1 exported to the infected RBC surface binds to the A and B blood group antigens and increases rosetting Chen et al, 2000) . These in vitro investigations have been substantiated clinically by case-control studies which examined rosetting frequency in parasites harvested directly from infected individuals with type O and non-type O blood (Rowe et al, 2007) . The obvious question thus remains, why is blood group O not nearly universally present in areas of high malaria endemicity? This condition is probably under balancing selection, as there is evidence of increased association of other infectious agents (i.e. cholera, Escherichia coli) with type O blood group (Rowe et al, 2009 ).
Duffy antigen receptor for chemokines
Although P. vivax malaria is not the focus here, perhaps one of the most compelling pieces of evidence for RBC evolution against malaria is the RBC surface protein Duffy antigen receptor for chemokines (DARC, also termed ACKR1). DARC is nearly absent from individuals in West and Central Africa. The Duffy blood group is determined by two codominant alleles (Fy*A and Fy*B) coding for FyA and FyB proteins. The common Sub-Saharan Africa phenotype is FyA-FyB-, resulting from a mutation in the ACKR1 (previously termed DARC, FY) gene promoter which affects GATA1 transcription factor binding -specifically, the GATA1 transcription factor for erythroid lineage cells (thus DARC expression elsewhere is unaffected) [(Tournamille et al, 1995) and reviewed in Livingstone (1984); Grimberg et al (2007) ]. Though continuous P. vivax cell culture remains impossible, in limited in vitro studies, invasion inhibition was demonstrated using antibodies targeting vivax's Duffy antigen binding protein (Miller et al, 1976; Grimberg et al, 2007; King et al, 2008) . Furthermore, closely related P. knowelsi parasites were shown to require DARC for merozoite tight junction formation during RBC invasion (Howes et al, 2015) . Invasion inability provides a clear mechanism for the relationship between Duffy antigen absence and P. vivax absence in much of Sub-Saharan Africa.
Despite the seemingly obvious evolutionary connection between the existence of Duffy negative blood groups (established at near 100% frequency in most of Africa) and P. vivax resistance, the causality has been questioned (Mu et al, 2005) . Some authors point out vivax malaria (at least in current form) is rarely severe or lethal and therefore is a weak evolutionary force. Others question how P. vivax could have influenced Duffy antigen absence across Africa given some evidence pointing towards origins in Asia where it is most prevalent today (Mu et al, 2005) . This point is also contested, however. In fact, very compelling recent research claims the opposite, that P. vivax originated in non-human primates in Africa (Escalante et al, 2005) , which correlates with the simplest explanation for why most Africans lack DARC. Regardless of the geographic origin of P. vivax and DARC prevalence, the belief that P. vivax is totally absent from Africa is far from accurate (Howes et al, 2015) . Plasmodium vivax existence in Africa relates to multiple factors: a small population of Duffy-positive individuals (particularly in parts of East Africa and Madagascar), possible zoonotic infection, and also parasite exploitation of alternative invasion routes in Duffy-negative individuals. Indeed, emerging evidence proves Duffy antigen-negative individuals can support P. vivax infection -coming from such diverse regions as Mauritania, Equatorial Guinea, Cameroon, Ethiopia, Angola, Madagascar, Kenya and even Brazil, which is cause for renewed scrutiny of the potential P. vivax burden in Africa (Howes et al, 2015) .
New malaria candidate genes involved with RBC function
The possibility of undertaking large scale genetic studies across different countries and using a standardized study design, particularly of severe malaria across sites, has enabled investigators to confirm the association of previously identified genetic variants and to identify new candidate genes. Recently, a study developed by the Malaria Genomic Epidemiology Network (https://www.malariagen.net/) involving over 11 000 African children, with replication studies in a further 14 000 individuals, has reported a novel falciparum malaria resistance locus close to a cluster of genes encoding glycophorins (Band et al, 2015) . The strongest signal of association was located between the gene FREM3 and a cluster of three glycophorin genes (GYPE, GYPB and GYPA). Glycophorins are RBC membrane proteins rich in sialic acids that are abundantly expressed in the erythrocyte membrane, providing a surface coat important for the flow of RBCs in circulation. These genes determine the MNS blood group system and have a functional role in invasion of erythrocytes by P. falciparum. A candidate region close to the glycophorins was also identified in a large cohort of Tanzanian children (Manjurano et al, 2015) . This initial finding has since been followed up with more detailed genome sequence analyses of individuals from Sub-Saharan Africa, finding a new association between a complex glycophorin copy number variant called DUP4 (predicted to result in a hybrid glycophorin B-A protein product representative of the Dantu blood group) that correlates with a 40% reduction in severe malaria (Leffler et al, 2017 ).
An increase in genetic variations in the glycophorin genes is observed in African populations. For example, RBCs from individuals with GYPB deletions (the S-s-U-blood group), which is frequently seen in the Efe pygmies found in the Democratic Republic of Congo, has been shown to be resistant to invasion by P. falciparum (Mayer et al, 2009) . Likewise, in Melanesia the frequency of the deletion of exon 3 in GYPC matches the distribution of malaria transmission, and its frequency reaches more than 50% in regions where malaria is hyperendemic. Plasmodium falciparum uses GYPC as an invasion pathway into the RBC (Maier et al, 2003) . Finally, the authors of the most recent MalariaGEN publication show the DUP4 variant, though rare, is present and gaining frequency in East Africa whereas it is absent from West Africa (Leffler et al, 2017) . This highlights the still dynamic nature of human-parasite evolution and our changing understanding of these genetic connections (Leffler et al, 2017) . It is thus possible that several genetic polymorphisms in the glycophorin genes reduce the invasion rate of the malaria parasite into the RBC, helping to control infection and keep parasitaemia low. Interestingly, these GWAS studies, identifying the importance of certain glycophorin variations in severe malaria susceptibility, confirm evidence provided by very early in vitro studies that examined different invasion rates into RBCs harbouring different glycophorin A and B mutations (Pasvol et al, 1982) . Glycophorins might also be involved in rosetting. GYPA on erythrocytes of blood group A also binds to parasite RIFINs (a P. falciparum large antigen gene family), forming large rosettes of infected erythrocytes: Smaller rosettes form with RBCs from individuals with blood group O (Goel et al, 2015) .
Another new RBC candidate for association with malaria infection identified through MalariaGEN is the ATP2B4 gene (Malaria Genomic Epidemiology Network, 2014) . This gene encodes the main calcium pump of the RBC plasma membrane, Ca 2+ -ATPase type 4 (PMCA4). Because PMCA4 is the major Ca 2+ pump of RBCs, alteration of its expression may disturb the homeostasis of intra-erythrocytic Ca 2+ concentrations. Genetic variation may therefore influence the expression of PMCA4 or the structural properties of the RBC, which could affect the parasite development through impairing replication or maturation during the intra-erythrocytic stage. A common ATP2B4 polymorphism was also identified as protective against malaria in pregnancy in a study of pregnant Ghanaian women (Bedu-Addo et al, 2013) . The fact that this ATP2B4 variant is associated with protection from severe disease and also acts against malaria in pregnancy suggests that there are multiple protective mechanisms involved. Overall, with expanding technical abilities to comprehensively evaluate genetic polymorphisms associated with malaria susceptibility, as seen with the contributions from MalariaGEN studies, the field continues to find new significant linkages to disease susceptibility, as well as confirm past research spanning several decades identifying associations between RBC alterations and malaria pressure, and furthermore rule out other polymorphisms once thought to be potentially associated with malaria. This genetic research will continue to be an important line of work in expanding our understanding of malaria pathogenesis and the impact on human RBC evolution. Other research developments that may elucidate further relationships between RBC polymorphisms and malaria pathogenesis are forthcoming. For example, worth mentioning is the newly identified PIEZO1 channel, a mechanically activated cation channel found in eukaryotic cell membranes. In RBCs, PIEZO1 has been determined to regulate mechanotransductive release of ATP, and it has been shown that PIEZO1 mutations reduce the amount of shear-induced ATP release and Ca 2+ influx (Cinar et al, 2015) . In relation to malaria, RBC ATP release and Ca 2+ influx are important factors involved in merozoite invasion. In fact, it has recently been shown that merozoite attachment induces phosphorylation of the PIEZO1 protein on RBCs (Zuccala et al, 2016) . Human PIEZO1 mutations are known to be associated with the rare hereditary xerocytosis, which involves RBC dehydration and haemolytic anaemia (Zarychanski et al, 2012) . It is highly conceivable that PIEZO1 polymorphisms affecting ATP release may impair merozoite invasion induction, potentially reducing malaria pathogenesis -a topic that will be interesting to follow in the context of human RBC alterations impacting malaria susceptibility. Finally, our own recent research on the relationship between nutritional immunity, anaemia and malaria pathogenesis offers another new line of research. Using an in vitro model, we determined parasite growth was significantly reduced in RBCs from iron-deficient individuals, involving both reduced invasion and replication, but not altered parasite maturation. We hypothesize iron deficiency anaemia alters RBC membrane physiology to limit parasite invasion as one of the primary drivers of protection in this model (Clark et al, 2014) . In a more extensive study using RBCs from anaemic Gambian children, we have identified a direct, positive correlation between RBC haemoglobin levels and parasite growth in vitro. In fact, parasite growth reduction due to anaemia was on par with growth reduction observed in RBCs from children with sickle-trait in vitro. Considering that anaemia is far more prevalent than sickle-cell trait in many malaria endemic areas, this suggests anaemia may offer more population-level malaria protection than even the most famous RBC evolutionary adaptations to malaria. There is also extensive clinical evidence suggesting iron deficiency is protective against malaria infection (Nyakeriga et al, 2004; Kabyemela et al, 2008; Gwamaka et al, 2011; Senga et al, 2011) , as well as evidence showing people of African descent have lower baseline haemoglobin values and RBC mean corpuscular volume (Dallman et al, 1978; Garn et al, 1981; Williams, 1981; Perry et al, 1992; Beutler & West, 2005) . More research into genetic causes of anaemia and lower haemoglobin values in people of African descent could lead to further understanding of whether anaemia prevalence is, at least in part, historically related to malaria pressure.
Conclusions
This review has focused on potential associations between malaria protection and human genetic alterations in RBC proteins. The extensive MalariaGEN studies are clearly opening new doors to understanding the impact of malaria pressure on human RBC polymorphisms and thus further contributing to our knowledge of malaria pathogenesis. Certainly, the most significant genetic association and functional studies examining link to malaria have also pointed to the importance of genes related to cell types beyond the RBC, though their role might be more difficult to pinpoint in genetic association studies. This would include inflammatory and immune factors as well as endothelial alterations. Still, humans and Plasmodium parasites have been at war for centuries, and one of the key evolutionary battlegrounds is indisputably the human RBC. Better understanding of malaria pathogenesis in the face of altered RBC physiology will ultimately help improve our strategies to combat the disease.
